Table 1. Platelet adhesion to DXR-treated EC.

Treatment	Mean Objects Number	SD	n	% control	% DXR	DXR vs Control	Treatment vs DXR
Control	40	10	8
DXR	231	40	8	577		P<0.001
DXR+eptifibatide	127	41	4		55		p<0.05
DXR+anti CD40L	188	42	4		81		p<0.05
DXR+Normal IgG	297	74	2		128
DXR+anti CD42b	215	77	4		93

EC were pretreated without (Control) or with DXR (100 µM) for 4 hr then washed 3 times and exposed to whole blood (0.2 ml) pretreated for 15 min with eptifibatide (20 µg/ml) or mAb against human CD154 (CD40L; 20 µg/ml) or mAb against human CD42b (GPIb; 20 µg/ml) or normal IgG (20 µg/ml) as control under flow conditions (750 s^-1) for 5 min using the CPA technology. The EC surface was then washed and the adhered platelets were immune-labeled using the anti-platelet CD41a specific antibody and the Histostain-Plus staining kit. The number of objects (platelets) on the EC surface was quantitated by the Impact-R image analyzer. Significant differences were assessed by the Kruskal-Wallis test (1 way ANOVA – non parametric) Dunn’s Multiple comparison test. Results were considered statistically significant at P<0.05.